N-acetylcysteine Stabilization via Buffer and Chelator Systems
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional treatments for external otitis and otitis media, particularly in the veterinary field, face challenges due to the instability and unpleasant odor of N-acetylcysteine, which limits its commercial use and effectiveness in preventing and treating these conditions, and the development of antibiotic resistance.
Innovation Solution
A pharmaceutical composition combining N-acetylcysteine with a stabilizing agent, such as TRIS and EDTA, which maintains the stability and odorlessness of N-acetylcysteine, preventing its degradation and allowing for effective use in treating otitis without resistance issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If N-acetylcysteine is used to treat bacterial infections and disintegrate biofilms, then therapeutic efficacy is improved, but the composition develops unpleasant odor and degrades under storage
Solution Approach 1:
The patent introduces buffer compounds (TRIS, PIPES, HEPES) and sequestering compounds (EDTA) as intermediary substances that mediate between N-acetylcysteine and the storage environment. These intermediaries buffer pH changes and chelate metal ions that would otherwise catalyze degradation, thereby maintaining stability without compromising the therapeutic action of N-acetylcysteine against biofilms
Solution Approach 2:
The patent systematically optimizes pH and compositional parameters to prevent degradation. By maintaining pH within 6.0-8.0 through buffer systems and controlling the presence of metal ions via sequestering agents, the patent changes the storage conditions to a parameter regime where N-acetylcysteine remains stable yet retains its biofilm-disintegrating efficacy
2Reliability
If N-acetylcysteine is used at high concentrations to reduce biofilm mass, then therapeutic effect is improved, but odor and degradation increase significantly
Solution Approach 1:
Buffer and sequestering compounds act as intermediaries that protect N-acetylcysteine from degradation even at high concentrations. This protection prevents the formation of odorous degradation products while allowing sufficient N-acetylcysteine to remain active for effective biofilm disintegration
Solution Approach 2:
The patent converts the potential harm of high concentration (odor and degradation) into benefit by using buffer and sequestering compounds to stabilize the molecule. The very conditions that would normally cause degradation (higher concentrations over time) are transformed into an opportunity to demonstrate the stabilizing effect of the buffer system, maintaining both efficacy and acceptability
3Reliability
If conventional antibiotic therapies are used to treat otitis, then bacterial infections are eliminated, but antibiotic resistance develops
Solution Approach 1:
The patent extracts the therapeutic function of eliminating bacterial biofilms from conventional antibiotics and transfers it to N-acetylcysteine. By removing N-acetylcysteine from its traditional role as an antioxidant and positioning it as a biofilm-disintegrating agent, the patent creates a new therapeutic approach that achieves infection control without the resistance problem associated with antibiotics
Solution Approach 2:
The patent employs a non-antibiotic mechanism (biofilm disintegration rather than bacterial killing) that does not select for resistance. N-acetylcysteine acts as a disposable agent that physically disrupts biofilm structure without exerting selective pressure on bacterial populations, thereby avoiding the development of resistance while maintaining treatment efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively stabilizes N-acetylcysteine, maintaining its efficacy and odorlessness under storage conditions, enabling its use in treating external and middle ear infections without the drawbacks of conventional antibiotics, including resistance and unpleasant odors.
Implementation Method 1
N-acetylcysteine contains a free thiol group, it acts as an antioxidant
Implementation Method 2
said stabilizing agent comprises a buffer compound selected from TRIS, PIPES, HEPES
Implementation Method 3
said stabilizing agent comprises a sequestering compound, in particular EDTA
Data Source
AI summary
A pharmaceutical composition is described for the prevention and treatment of external otitis or otitis media, in particular in the veterinary field. The composition of the invention comprises a synergistic association of N-acetylcysteine and a stabilizing agent, which has been shown to be significantly active against pathogens causing the external otitis, at the same time significantly reducing the disadvantages of N-acetylcysteine.